Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18703960 | 0.93 | FPR2 (0.86) | FPR2 | |
| SCHEMBL21698099 | 0.87 | FPR2 (1.00) | FPR2 | |
| SCHEMBL17286106 | 0.87 | FPR2 (1.00) | FPR2 | |
| SCHEMBL21669953 | 0.84 | FPR2 (1.00) | FPR2 | |
| SCHEMBL17286096 | 0.84 | FPR2 (1.00) | FPR2 | |
| SCHEMBL18704000 | 0.77 | FPR2 (0.84) | FPR2 | |
| SCHEMBL21669948 | 0.77 | FPR2 (1.00) | FPR2 | |
| SCHEMBL17286105 | 0.77 | FPR2 (1.00) | FPR2 | |
| SCHEMBL18703959 | 0.76 | FPR2 (0.84) | FPR2 | |
| SCHEMBL21669952 | 0.75 | FPR2 (1.00) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800744-B2 | Imidazole derivatives as formyl peptide receptor modulators | ALLERGAN, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800744-B2 | Imidazole derivatives as formyl peptide receptor modulators | ALLERGAN, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200115346-A1 | IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-16 | — | — | US | disclosed |
| EP-3145916-B1 | IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3145916-B1 | IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10301269-B2 | Imidazole derivatives as formyl peptide receptor modulators | ALLERGAN, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301269-B2 | Imidazole derivatives as formyl peptide receptor modulators | ALLERGAN, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170096401-A1 | IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096401-A1 | IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096401-A1 | IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2015179707-A1 | IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115346-A1 | IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | FPR1, FPR3, FPR2 | FPR2 3/4885 |
| US-20170096401-A1 | IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | FPR1, FPR3, FPR2 | FPR2 3/4885 |
| US-10301269-B2 | Imidazole derivatives as formyl peptide receptor modulators | FPR1, FPR3, FPR2 | FPR2 3/4885 |
| US-10800744-B2 | Imidazole derivatives as formyl peptide receptor modulators | FPR1, FPR3, FPR2 | FPR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.